Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

ITK inhibitors may effectively treat alopecia areata.

In this study, aumolertinib improved general health status, functional status, and key symptoms for patients with advanced NSCLC, with an objective response rate of 65.2% and disease control rate of 91.3%, suggesting efficacy and quality of life benefits in first-line treatment.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

This study found that skin exposure to toluene diisocyanate in mice creates immune-recognition reservoirs in the skin's stratum corneum and hair follicles, potentially leading to sensitization and allergic reactions.

A specific hair protein variant increases the spread of breast cancer and is linked to worse survival rates.

This Patent Highlight discusses recent progress in developing TYK2 inhibitors, which show potential for treating conditions like cancer, alopecia areata, and psoriatic arthritis.

This study optimized a screening assay to identify molecules that inhibit or enhance TRPM5 ion channel activity, which may have implications for treating dysfunctions linked to cardiac arrhythmias and diabetes.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This study found that Trichosanthes kirilowii extract significantly enhances keratinocyte proliferation and wound healing in vitro and in vivo, suggesting its potential as a wound-healing component.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

In this study on New Zealand white rabbits, the researchers reported that a hair tonic formula combining bitter melon leaf and carrot extracts resulted in optimal hair growth, particularly at a 3:1 ratio and a concentration of 3%, without causing irritation.

This systematic review details monitoring and safety guidelines for primary care physicians regarding Janus kinase and tyrosine kinase 2 inhibitors used in treating inflammatory skin conditions, emphasizing their efficacy and the importance of updated knowledge due to associated box warnings and increasing use.

This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.

This case report describes a rare instance of renal cell carcinoma metastasizing to the ovary and early onset of alopecia after beginning sunitinib treatment, though hypothyroidism and dandruff complicate attribution to the drug.

This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.

This study found that Tianqi trichogen promoted hair growth in tested animals, with no observed photoallergic reactions or significant skin allergies.

In this study, inactivating the TAF4 subunit of transcription factor TFIID in mouse epidermis disrupted gene expression linked to skin and hair function, and increased tumor risk.

This review discusses the roles of KIT and mast cells in skin physiology and pathology using different genetic models and reports no new clinical results; the authors suggest further exploration of KIT deficiency.

TAK-279 effectively reduces psoriasis symptoms and is safe.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

This study developed a novel monoclonal antibody, TYHF-1, which specifically reacts with hair keratins but not with epidermal keratins or various other tissue cells.

CTP-543 is generally safe for treating alopecia areata.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This study found that hinokitiol effectively suppressed TNF-α production in activated macrophage-like cells, suggesting it may help alleviate hair loss by mitigating factors that promote follicular apoptosis.

In this study, researchers identified Tenascin-C as a marker for touch dome keratinocytes, which maintain themselves and can develop into Merkel cells following injury, showing they share molecular traits with various epidermal keratinocytes.

This article discusses the introduction and market presence of the Italian hair product Kevis but presents no new clinical findings.

This study found that applying TPA to mice accelerated hair follicle regeneration by activating Akt and Wnt/ß-catenin signaling pathways, involving hair follicle stem cell proliferation.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.